APO Research
Talk to an analyst

APO RESEARCH · REPORT

Axial Spondyloarthritis Medications

Compare research editions
View pricing & licenses

Selected research

Industry Research

Axial Spondyloarthritis Medications Industry Research Report 2026

28 December 2025131 pages

Choose your research edition.

Industry ResearchAxial Spondyloarthritis Medications Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Axial Spondyloarthritis Medications Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Axial Spondyloarthritis Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Axial Spondyloarthritis Medications Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Axial Spondyloarthritis Medications Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Axial Spondyloarthritis Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Axial Spondyloarthritis Medications is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Axial Spondyloarthritis Medications is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Axial Spondyloarthritis Medications is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Axial Spondyloarthritis Medications include Abbott, Johnson & Johnson, Novartis, Pfizer, Bayer, Verywell, UCB, Sun Pharmaceutical Industries and Reddy Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Axial Spondyloarthritis Medications market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Axial Spondyloarthritis Medications Market by Company

Abbott

Johnson & Johnson

Novartis

Pfizer

Bayer

Verywell

UCB

Sun Pharmaceutical Industries

Reddy Pharmaceuticals

Perrigo Company

Novacap

Merck Sharp & Dohme

Kopran

GlaxoSmithKline

Geri-Care Pharmaceuticals

Eli Lilly and Co.

DICE Therapeutics

Cigna

AstraZeneca

Axial Spondyloarthritis Medications Segment by Type

Injection

Oral

Axial Spondyloarthritis Medications Segment by Application

Hospital

Clinic

Other

Axial Spondyloarthritis Medications Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Axial Spondyloarthritis Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Axial Spondyloarthritis Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Axial Spondyloarthritis Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Axial Spondyloarthritis Medications manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Axial Spondyloarthritis Medications by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Axial Spondyloarthritis Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Axial Spondyloarthritis Medications Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Axial Spondyloarthritis Medications Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Axial Spondyloarthritis Medications Sales Market Share by Manufacturers (2021-2026) Table 8. Global Axial Spondyloarthritis Medications Revenue of Manufacturers (2021-2026) Table 9. Global Axial Spondyloarthritis Medications Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Axial Spondyloarthritis Medications Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Axial Spondyloarthritis Medications Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Axial Spondyloarthritis Medications, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Axial Spondyloarthritis Medications, Product Type & Application Table 14. Global Axial Spondyloarthritis Medications Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Axial Spondyloarthritis Medications by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Abbott Company Information Table 19. Abbott Business Overview Table 20. Abbott Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Abbott Axial Spondyloarthritis Medications Product Portfolio Table 22. Abbott Recent Developments Table 23. Johnson & Johnson Company Information Table 24. Johnson & Johnson Business Overview Table 25. Johnson & Johnson Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Johnson & Johnson Axial Spondyloarthritis Medications Product Portfolio Table 27. Johnson & Johnson Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis Axial Spondyloarthritis Medications Product Portfolio Table 32. Novartis Recent Developments Table 33. Pfizer Company Information Table 34. Pfizer Business Overview Table 35. Pfizer Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Pfizer Axial Spondyloarthritis Medications Product Portfolio Table 37. Pfizer Recent Developments Table 38. Bayer Company Information Table 39. Bayer Business Overview Table 40. Bayer Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Bayer Axial Spondyloarthritis Medications Product Portfolio Table 42. Bayer Recent Developments Table 43. Verywell Company Information Table 44. Verywell Business Overview Table 45. Verywell Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Verywell Axial Spondyloarthritis Medications Product Portfolio Table 47. Verywell Recent Developments Table 48. UCB Company Information Table 49. UCB Business Overview Table 50. UCB Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. UCB Axial Spondyloarthritis Medications Product Portfolio Table 52. UCB Recent Developments Table 53. Sun Pharmaceutical Industries Company Information Table 54. Sun Pharmaceutical Industries Business Overview Table 55. Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Product Portfolio Table 57. Sun Pharmaceutical Industries Recent Developments Table 58. Reddy Pharmaceuticals Company Information Table 59. Reddy Pharmaceuticals Business Overview Table 60. Reddy Pharmaceuticals Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Reddy Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio Table 62. Reddy Pharmaceuticals Recent Developments Table 63. Perrigo Company Company Information Table 64. Perrigo Company Business Overview Table 65. Perrigo Company Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Perrigo Company Axial Spondyloarthritis Medications Product Portfolio Table 67. Perrigo Company Recent Developments Table 68. Novacap Company Information Table 69. Novacap Business Overview Table 70. Novacap Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Novacap Axial Spondyloarthritis Medications Product Portfolio Table 72. Novacap Recent Developments Table 73. Merck Sharp & Dohme Company Information Table 74. Merck Sharp & Dohme Business Overview Table 75. Merck Sharp & Dohme Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Merck Sharp & Dohme Axial Spondyloarthritis Medications Product Portfolio Table 77. Merck Sharp & Dohme Recent Developments Table 78. Kopran Company Information Table 79. Kopran Business Overview Table 80. Kopran Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Kopran Axial Spondyloarthritis Medications Product Portfolio Table 82. Kopran Recent Developments Table 83. GlaxoSmithKline Company Information Table 84. GlaxoSmithKline Business Overview Table 85. GlaxoSmithKline Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Axial Spondyloarthritis Medications Product Portfolio Table 87. GlaxoSmithKline Recent Developments Table 88. Geri-Care Pharmaceuticals Company Information Table 89. Geri-Care Pharmaceuticals Business Overview Table 90. Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio Table 92. Geri-Care Pharmaceuticals Recent Developments Table 93. Eli Lilly and Co. Company Information Table 94. Eli Lilly and Co. Business Overview Table 95. Eli Lilly and Co. Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Eli Lilly and Co. Axial Spondyloarthritis Medications Product Portfolio Table 97. Eli Lilly and Co. Recent Developments Table 98. DICE Therapeutics Company Information Table 99. DICE Therapeutics Business Overview Table 100. DICE Therapeutics Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. DICE Therapeutics Axial Spondyloarthritis Medications Product Portfolio Table 102. DICE Therapeutics Recent Developments Table 103. Cigna Company Information Table 104. Cigna Business Overview Table 105. Cigna Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Cigna Axial Spondyloarthritis Medications Product Portfolio Table 107. Cigna Recent Developments Table 108. AstraZeneca Company Information Table 109. AstraZeneca Business Overview Table 110. AstraZeneca Axial Spondyloarthritis Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. AstraZeneca Axial Spondyloarthritis Medications Product Portfolio Table 112. AstraZeneca Recent Developments Table 113. Global Axial Spondyloarthritis Medications Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Axial Spondyloarthritis Medications Sales by Region (2021-2026) & (K Units) Table 115. Global Axial Spondyloarthritis Medications Sales Market Share by Region (2021-2026) Table 116. Global Axial Spondyloarthritis Medications Sales by Region (2027-2032) & (K Units) Table 117. Global Axial Spondyloarthritis Medications Sales Market Share by Region (2027-2032) Table 118. Global Axial Spondyloarthritis Medications Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Axial Spondyloarthritis Medications Revenue Market Share by Region (2021-2026) Table 120. Global Axial Spondyloarthritis Medications Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Axial Spondyloarthritis Medications Revenue Market Share by Region (2027-2032) Table 122. North America Axial Spondyloarthritis Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Axial Spondyloarthritis Medications Sales by Country (2021-2026) & (K Units) Table 124. North America Axial Spondyloarthritis Medications Sales by Country (2027-2032) & (K Units) Table 125. North America Axial Spondyloarthritis Medications Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Axial Spondyloarthritis Medications Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Axial Spondyloarthritis Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Axial Spondyloarthritis Medications Sales by Country (2021-2026) & (K Units) Table 129. Europe Axial Spondyloarthritis Medications Sales by Country (2027-2032) & (K Units) Table 130. Europe Axial Spondyloarthritis Medications Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Axial Spondyloarthritis Medications Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Axial Spondyloarthritis Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Axial Spondyloarthritis Medications Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific Axial Spondyloarthritis Medications Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific Axial Spondyloarthritis Medications Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Axial Spondyloarthritis Medications Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Axial Spondyloarthritis Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Axial Spondyloarthritis Medications Sales by Country (2021-2026) & (K Units) Table 139. South America Axial Spondyloarthritis Medications Sales by Country (2027-2032) & (K Units) Table 140. South America Axial Spondyloarthritis Medications Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Axial Spondyloarthritis Medications Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Axial Spondyloarthritis Medications Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Axial Spondyloarthritis Medications Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa Axial Spondyloarthritis Medications Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa Axial Spondyloarthritis Medications Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Axial Spondyloarthritis Medications Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Axial Spondyloarthritis Medications Sales by Type (2021-2026) & (K Units) Table 148. Global Axial Spondyloarthritis Medications Sales by Type (2027-2032) & (K Units) Table 149. Global Axial Spondyloarthritis Medications Sales Market Share by Type (2021-2026) Table 150. Global Axial Spondyloarthritis Medications Sales Market Share by Type (2027-2032) Table 151. Global Axial Spondyloarthritis Medications Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Axial Spondyloarthritis Medications Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Axial Spondyloarthritis Medications Revenue Market Share by Type (2021-2026) Table 154. Global Axial Spondyloarthritis Medications Revenue Market Share by Type (2027-2032) Table 155. Global Axial Spondyloarthritis Medications Price by Type (2021-2026) & (US$/Unit) Table 156. Global Axial Spondyloarthritis Medications Price by Type (2027-2032) & (US$/Unit) Table 157. Global Axial Spondyloarthritis Medications Sales by Application (2021-2026) & (K Units) Table 158. Global Axial Spondyloarthritis Medications Sales by Application (2027-2032) & (K Units) Table 159. Global Axial Spondyloarthritis Medications Sales Market Share by Application (2021-2026) Table 160. Global Axial Spondyloarthritis Medications Sales Market Share by Application (2027-2032) Table 161. Global Axial Spondyloarthritis Medications Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Axial Spondyloarthritis Medications Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Axial Spondyloarthritis Medications Revenue Market Share by Application (2021-2026) Table 164. Global Axial Spondyloarthritis Medications Revenue Market Share by Application (2027-2032) Table 165. Global Axial Spondyloarthritis Medications Price by Application (2021-2026) & (US$/Unit) Table 166. Global Axial Spondyloarthritis Medications Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Axial Spondyloarthritis Medications Distributors List Table 170. Axial Spondyloarthritis Medications Customers List Table 171. Axial Spondyloarthritis Medications Industry Trends Table 172. Axial Spondyloarthritis Medications Industry Drivers Table 173. Axial Spondyloarthritis Medications Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Axial Spondyloarthritis Medications Product Image Figure 5. Global Axial Spondyloarthritis Medications Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Axial Spondyloarthritis Medications Market Size (2021-2032) & (US$ Million) Figure 7. Global Axial Spondyloarthritis Medications Sales (2021-2032) & (K Units) Figure 8. Global Axial Spondyloarthritis Medications Average Price (US$/Unit) & (2021-2032) Figure 9. Injection Product Image Figure 10. Oral Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Other Product Image Figure 14. Global Axial Spondyloarthritis Medications Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Axial Spondyloarthritis Medications, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Axial Spondyloarthritis Medications Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Axial Spondyloarthritis Medications Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Axial Spondyloarthritis Medications Sales by Region in 2025 Figure 20. Global Axial Spondyloarthritis Medications Revenue by Region in 2025 Figure 21. North America Axial Spondyloarthritis Medications Market Size by Country in 2025 Figure 22. North America Axial Spondyloarthritis Medications Sales Market Share by Country (2021-2032) Figure 23. North America Axial Spondyloarthritis Medications Revenue Market Share by Country (2021-2032) Figure 24. United States Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Axial Spondyloarthritis Medications Market Size by Country in 2025 Figure 28. Europe Axial Spondyloarthritis Medications Sales Market Share by Country (2021-2032) Figure 29. Europe Axial Spondyloarthritis Medications Revenue Market Share by Country (2021-2032) Figure 30. Germany Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Axial Spondyloarthritis Medications Market Size by Country in 2025 Figure 41. Asia Pacific Axial Spondyloarthritis Medications Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Axial Spondyloarthritis Medications Revenue Market Share by Country (2021-2032) Figure 43. China Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Axial Spondyloarthritis Medications Market Size by Country in 2025 Figure 52. South America Axial Spondyloarthritis Medications Sales Market Share by Country (2021-2032) Figure 53. South America Axial Spondyloarthritis Medications Revenue Market Share by Country (2021-2032) Figure 54. Brazil Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Axial Spondyloarthritis Medications Market Size by Country in 2025 Figure 58. Middle East and Africa Axial Spondyloarthritis Medications Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Axial Spondyloarthritis Medications Revenue Market Share by Country (2021-2032) Figure 60. Egypt Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Axial Spondyloarthritis Medications Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Axial Spondyloarthritis Medications Sales Market Share by Type (2021-2032) Figure 66. Global Axial Spondyloarthritis Medications Revenue Market Share by Type (2021-2032) Figure 67. Global Axial Spondyloarthritis Medications Price (US$/Unit) by Type (2021-2032) Figure 68. Global Axial Spondyloarthritis Medications Sales Market Share by Application (2021-2032) Figure 69. Global Axial Spondyloarthritis Medications Revenue Market Share by Application (2021-2032) Figure 70. Global Axial Spondyloarthritis Medications Price (US$/Unit) by Application (2021-2032) Figure 71. Axial Spondyloarthritis Medications Value Chain Figure 72. Axial Spondyloarthritis Medications Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Axial Spondyloarthritis Medications Industry Opportunities and Challenges

Scope & coverage.

Types
  • Injection
  • Oral
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Abbott
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Bayer
  • Verywell
  • UCB
  • Sun Pharmaceutical Industries
  • Reddy Pharmaceuticals
  • Perrigo Company
  • Novacap
  • Merck Sharp & Dohme
  • Kopran
  • GlaxoSmithKline
  • Geri-Care Pharmaceuticals
  • Eli Lilly and Co.
  • DICE Therapeutics
  • Cigna
  • AstraZeneca

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Axial Spondyloarthritis Medications Market Size (2021-2032)
  4. 2.2.2 Global Axial Spondyloarthritis Medications Sales (2021-2032)
  5. 2.2.3 Global Axial Spondyloarthritis Medications Market Average Price (2021-2032)
  6. 2.3 Axial Spondyloarthritis Medications by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Injection
  9. 2.3.3 Oral
  10. 2.4 Axial Spondyloarthritis Medications by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Axial Spondyloarthritis Medications Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Axial Spondyloarthritis Medications Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Axial Spondyloarthritis Medications Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Axial Spondyloarthritis Medications Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Axial Spondyloarthritis Medications Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Axial Spondyloarthritis Medications, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Axial Spondyloarthritis Medications, Product Type & Application
  8. 3.8 Global Manufacturers of Axial Spondyloarthritis Medications, Established Date
  9. 3.9 Global Axial Spondyloarthritis Medications Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abbott
  2. 4.1.1 Abbott Company Information
  3. 4.1.2 Abbott Business Overview
  4. 4.1.3 Abbott Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Abbott Axial Spondyloarthritis Medications Product Portfolio
  6. 4.1.5 Abbott Recent Developments
  7. 4.2 Johnson & Johnson
  8. 4.2.1 Johnson & Johnson Company Information
  9. 4.2.2 Johnson & Johnson Business Overview
  10. 4.2.3 Johnson & Johnson Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Johnson & Johnson Axial Spondyloarthritis Medications Product Portfolio
  12. 4.2.5 Johnson & Johnson Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Axial Spondyloarthritis Medications Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Pfizer
  20. 4.4.1 Pfizer Company Information
  21. 4.4.2 Pfizer Business Overview
  22. 4.4.3 Pfizer Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Pfizer Axial Spondyloarthritis Medications Product Portfolio
  24. 4.4.5 Pfizer Recent Developments
  25. 4.5 Bayer
  26. 4.5.1 Bayer Company Information
  27. 4.5.2 Bayer Business Overview
  28. 4.5.3 Bayer Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Bayer Axial Spondyloarthritis Medications Product Portfolio
  30. 4.5.5 Bayer Recent Developments
  31. 4.6 Verywell
  32. 4.6.1 Verywell Company Information
  33. 4.6.2 Verywell Business Overview
  34. 4.6.3 Verywell Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Verywell Axial Spondyloarthritis Medications Product Portfolio
  36. 4.6.5 Verywell Recent Developments
  37. 4.7 UCB
  38. 4.7.1 UCB Company Information
  39. 4.7.2 UCB Business Overview
  40. 4.7.3 UCB Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 UCB Axial Spondyloarthritis Medications Product Portfolio
  42. 4.7.5 UCB Recent Developments
  43. 4.8 Sun Pharmaceutical Industries
  44. 4.8.1 Sun Pharmaceutical Industries Company Information
  45. 4.8.2 Sun Pharmaceutical Industries Business Overview
  46. 4.8.3 Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sun Pharmaceutical Industries Axial Spondyloarthritis Medications Product Portfolio
  48. 4.8.5 Sun Pharmaceutical Industries Recent Developments
  49. 4.9 Reddy Pharmaceuticals
  50. 4.9.1 Reddy Pharmaceuticals Company Information
  51. 4.9.2 Reddy Pharmaceuticals Business Overview
  52. 4.9.3 Reddy Pharmaceuticals Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Reddy Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio
  54. 4.9.5 Reddy Pharmaceuticals Recent Developments
  55. 4.10 Perrigo Company
  56. 4.10.1 Perrigo Company Company Information
  57. 4.10.2 Perrigo Company Business Overview
  58. 4.10.3 Perrigo Company Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Perrigo Company Axial Spondyloarthritis Medications Product Portfolio
  60. 4.10.5 Perrigo Company Recent Developments
  61. 4.11 Novacap
  62. 4.11.1 Novacap Company Information
  63. 4.11.2 Novacap Business Overview
  64. 4.11.3 Novacap Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Novacap Axial Spondyloarthritis Medications Product Portfolio
  66. 4.11.5 Novacap Recent Developments
  67. 4.12 Merck Sharp & Dohme
  68. 4.12.1 Merck Sharp & Dohme Company Information
  69. 4.12.2 Merck Sharp & Dohme Business Overview
  70. 4.12.3 Merck Sharp & Dohme Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Merck Sharp & Dohme Axial Spondyloarthritis Medications Product Portfolio
  72. 4.12.5 Merck Sharp & Dohme Recent Developments
  73. 4.13 Kopran
  74. 4.13.1 Kopran Company Information
  75. 4.13.2 Kopran Business Overview
  76. 4.13.3 Kopran Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Kopran Axial Spondyloarthritis Medications Product Portfolio
  78. 4.13.5 Kopran Recent Developments
  79. 4.14 GlaxoSmithKline
  80. 4.14.1 GlaxoSmithKline Company Information
  81. 4.14.2 GlaxoSmithKline Business Overview
  82. 4.14.3 GlaxoSmithKline Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 GlaxoSmithKline Axial Spondyloarthritis Medications Product Portfolio
  84. 4.14.5 GlaxoSmithKline Recent Developments
  85. 4.15 Geri-Care Pharmaceuticals
  86. 4.15.1 Geri-Care Pharmaceuticals Company Information
  87. 4.15.2 Geri-Care Pharmaceuticals Business Overview
  88. 4.15.3 Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Geri-Care Pharmaceuticals Axial Spondyloarthritis Medications Product Portfolio
  90. 4.15.5 Geri-Care Pharmaceuticals Recent Developments
  91. 4.16 Eli Lilly and Co.
  92. 4.16.1 Eli Lilly and Co. Company Information
  93. 4.16.2 Eli Lilly and Co. Business Overview
  94. 4.16.3 Eli Lilly and Co. Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Eli Lilly and Co. Axial Spondyloarthritis Medications Product Portfolio
  96. 4.16.5 Eli Lilly and Co. Recent Developments
  97. 4.17 DICE Therapeutics
  98. 4.17.1 DICE Therapeutics Company Information
  99. 4.17.2 DICE Therapeutics Business Overview
  100. 4.17.3 DICE Therapeutics Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 DICE Therapeutics Axial Spondyloarthritis Medications Product Portfolio
  102. 4.17.5 DICE Therapeutics Recent Developments
  103. 4.18 Cigna
  104. 4.18.1 Cigna Company Information
  105. 4.18.2 Cigna Business Overview
  106. 4.18.3 Cigna Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Cigna Axial Spondyloarthritis Medications Product Portfolio
  108. 4.18.5 Cigna Recent Developments
  109. 4.19 AstraZeneca
  110. 4.19.1 AstraZeneca Company Information
  111. 4.19.2 AstraZeneca Business Overview
  112. 4.19.3 AstraZeneca Axial Spondyloarthritis Medications Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 AstraZeneca Axial Spondyloarthritis Medications Product Portfolio
  114. 4.19.5 AstraZeneca Recent Developments
5 Global Axial Spondyloarthritis Medications Market Scenario by Region
  1. 5.1 Global Axial Spondyloarthritis Medications Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Axial Spondyloarthritis Medications Sales by Region: 2021-2032
  3. 5.2.1 Global Axial Spondyloarthritis Medications Sales by Region: 2021-2026
  4. 5.2.2 Global Axial Spondyloarthritis Medications Sales by Region: 2027-2032
  5. 5.3 Global Axial Spondyloarthritis Medications Revenue by Region: 2021-2032
  6. 5.3.1 Global Axial Spondyloarthritis Medications Revenue by Region: 2021-2026
  7. 5.3.2 Global Axial Spondyloarthritis Medications Revenue by Region: 2027-2032
  8. 5.4 North America Axial Spondyloarthritis Medications Market Facts & Figures by Country
  9. 5.4.1 North America Axial Spondyloarthritis Medications Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Axial Spondyloarthritis Medications Sales by Country (2021-2032)
  11. 5.4.3 North America Axial Spondyloarthritis Medications Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Axial Spondyloarthritis Medications Market Facts & Figures by Country
  16. 5.5.1 Europe Axial Spondyloarthritis Medications Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Axial Spondyloarthritis Medications Sales by Country (2021-2032)
  18. 5.5.3 Europe Axial Spondyloarthritis Medications Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Axial Spondyloarthritis Medications Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Axial Spondyloarthritis Medications Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Axial Spondyloarthritis Medications Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Axial Spondyloarthritis Medications Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Axial Spondyloarthritis Medications Market Facts & Figures by Country
  41. 5.7.1 South America Axial Spondyloarthritis Medications Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Axial Spondyloarthritis Medications Sales by Country (2021-2032)
  43. 5.7.3 South America Axial Spondyloarthritis Medications Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Axial Spondyloarthritis Medications Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Axial Spondyloarthritis Medications Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Axial Spondyloarthritis Medications Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Axial Spondyloarthritis Medications Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Axial Spondyloarthritis Medications Sales by Type (2021-2032)
  2. 6.1.1 Global Axial Spondyloarthritis Medications Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Axial Spondyloarthritis Medications Sales Market Share by Type (2021-2032)
  4. 6.2 Global Axial Spondyloarthritis Medications Revenue by Type (2021-2032)
  5. 6.2.1 Global Axial Spondyloarthritis Medications Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Axial Spondyloarthritis Medications Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Axial Spondyloarthritis Medications Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Axial Spondyloarthritis Medications Sales by Application (2021-2032)
  2. 7.1.1 Global Axial Spondyloarthritis Medications Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Axial Spondyloarthritis Medications Sales Market Share by Application (2021-2032)
  4. 7.2 Global Axial Spondyloarthritis Medications Revenue by Application (2021-2032)
  5. 7.2.1 Global Axial Spondyloarthritis Medications Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Axial Spondyloarthritis Medications Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Axial Spondyloarthritis Medications Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Axial Spondyloarthritis Medications Value Chain Analysis
  2. 8.1.1 Axial Spondyloarthritis Medications Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Axial Spondyloarthritis Medications Production Mode & Process
  5. 8.2 Axial Spondyloarthritis Medications Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Axial Spondyloarthritis Medications Distributors
  8. 8.2.3 Axial Spondyloarthritis Medications Customers
9 Global Axial Spondyloarthritis Medications Analyzing Market Dynamics
  1. 9.1 Axial Spondyloarthritis Medications Industry Trends
  2. 9.2 Axial Spondyloarthritis Medications Industry Drivers
  3. 9.3 Axial Spondyloarthritis Medications Industry Opportunities and Challenges
  4. 9.4 Axial Spondyloarthritis Medications Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst